$KRON
Kronos Bio, Inc. Stock $kron

$kron Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000174183022000017 Filed on May 04, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$12.69M	$9.590M
YoY Change	32.37%	580.14%
% of Gross Profit
Research & Development	$24.44M	$17.59M
YoY Change	38.9%	184.0%
% of Gross Profit
Depreciation & Amortization	$600.0K	$400.0K
YoY Change	50.0%	100.0%
% of Gross Profit
Operating Expenses	$36.37M	$26.18M
YoY Change	38.91%	256.21%
Operating Profit	-$36.37M	-$26.18M
YoY Change	38.91%	256.21%
Interest Expense	$102.0K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	$102.0K	$92.00K
YoY Change	10.87%	-74.01%
Pretax Income	-$36.26M	-$26.09M
YoY Change	38.99%	272.71%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$36.26M	-$26.09M
YoY Change	39.01%	272.92%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.65	-$0.48
Diluted Earnings Per Share	-$0.65	-$0.48
COMMON SHARES
Basic Shares Outstanding	55.84M shares	54.15M shares
Diluted Shares Outstanding	55.84M shares	54.15M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$303.1M	$398.9M
YoY Change	-24.01%
Cash & Equivalents	$149.0M	$141.4M
Short-Term Investments	$154.2M	$257.5M
Other Short-Term Assets	$6.794M	$5.100M
YoY Change	33.22%
Inventory
Prepaid Expenses
Receivables	$661.0K	$1.300M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$310.6M	$405.3M
YoY Change	-23.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.88M	$38.90M
YoY Change	5.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$12.25M	$41.70M
YoY Change	-70.63%
Other Assets	$113.0K	$114.0K
YoY Change	-0.88%
Total Long-Term Assets	$55.27M	$82.69M
YoY Change	-33.17%
TOTAL ASSETS
Total Short-Term Assets	$310.6M	$405.3M
Total Long-Term Assets	$55.27M	$82.69M
Total Assets	$365.9M	$488.0M
YoY Change	-25.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.719M	$3.586M
YoY Change	31.6%
Accrued Expenses	$8.328M	$4.275M
YoY Change	94.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change
Total Short-Term Liabilities	$17.08M	$11.29M
YoY Change	51.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$795.0K	$2.025M
YoY Change	-60.74%
Total Long-Term Liabilities	$795.0K	$2.025M
YoY Change	-60.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.08M	$11.29M
Total Long-Term Liabilities	$795.0K	$2.025M
Total Liabilities	$48.84M	$42.70M
YoY Change	14.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$299.2M	-$138.0M
YoY Change	116.86%
Common Stock	$56.00K	$54.00K
YoY Change	3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$317.0M	$445.3M
YoY Change
Total Liabilities & Shareholders Equity	$365.9M	$488.0M
YoY Change	-25.02%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$36.26M	-$26.09M
YoY Change	39.01%	272.92%
Depreciation, Depletion And Amortization	$600.0K	$400.0K
YoY Change	50.0%	100.0%
Cash From Operating Activities	-$23.48M	-$19.00M
YoY Change	23.61%	168.86%
INVESTING ACTIVITIES
Capital Expenditures	$366.0K	$1.505M
YoY Change	-75.68%	140.42%
Acquisitions
YoY Change
Other Investing Activities	-$25.97M	-$86.64M
YoY Change	-70.03%	-1558.59%
Cash From Investing Activities	-$26.34M	-$88.15M
YoY Change	-70.12%	-1760.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$590.0K
YoY Change		2850.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$529.0K	$585.0K
YoY Change	-9.57%	4775.0%
NET CHANGE
Cash From Operating Activities	-$23.48M	-$19.00M
Cash From Investing Activities	-$26.34M	-$88.15M
Cash From Financing Activities	$529.0K	$585.0K
Net Change In Cash	-$49.29M	-$106.6M
YoY Change	-53.74%	6010.21%
FREE CASH FLOW
Cash From Operating Activities	-$23.48M	-$19.00M
Capital Expenditures	$366.0K	$1.505M
Free Cash Flow	-$23.85M	-$20.50M
YoY Change	16.32%	166.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001741830
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-39592
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Kronos Bio, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1895605
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1300 So. El Camino Real
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Mateo
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94402
CY2022Q1	dei	City Area Code CityAreaCode	650
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	781-5200
CY2022Q1	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2022Q1	dei	Trading Symbol TradingSymbol	KRON
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56732201	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148979000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	112000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	198270000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	154157000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	141239000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7455000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8045000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	310591000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	347554000	USD
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	12246000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14510000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14880000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26370000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26904000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	113000	USD
CY2022Q1	us-gaap	Assets Assets	365856000	USD
CY2021Q4	us-gaap	Assets Assets	391476000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4719000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	998000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8328000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9063000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2502000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2109000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1529000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1456000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17078000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13626000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30963000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31653000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	795000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1100000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	48836000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	46379000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56064509	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56064509	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55703327	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55703327	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	56000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	56000	USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	616381000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	608064000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-299247000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262984000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-170000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-39000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	317020000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	345097000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	365856000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	391476000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24438000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17594000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11927000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8584000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	36365000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	26178000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-36365000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26178000	USD
CY2022Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	102000	USD
CY2021Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	92000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	102000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	92000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36263000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-26086000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-131000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36394000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26090000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55839336	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55839336	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54152656	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54152656	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	345097000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	529000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7788000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-131000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36263000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	317020000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	465519000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	590000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5238000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-26086000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	445257000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36263000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-26086000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	557000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	444000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-517000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-943000	USD
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-343000	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-16000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7788000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5238000	USD
CY2022Q1	kron	Lease Expense Noncash LeaseExpenseNoncash	534000	USD
CY2021Q1	kron	Lease Expense Noncash LeaseExpenseNoncash	461000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-406000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-971000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-52000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3670000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1199000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-505000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	228000	USD
CY2022Q1	kron	Increase Decrease In Right Of Use Operating Assets And Liabilities Net IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet	297000	USD
CY2021Q1	kron	Increase Decrease In Right Of Use Operating Assets And Liabilities Net IncreaseDecreaseInRightOfUseOperatingAssetsAndLiabilitiesNet	-175000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-233000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-241000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23484000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18998000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	366000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1505000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	94544000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	126060000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	68574000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	39416000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-26336000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-88149000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	529000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	590000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	529000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	585000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49291000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-106562000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200296000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250036000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151005000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143474000	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	47000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	588000	USD
CY2022Q1	kron	Right Of Use Asset Increase Decrease Due To Modification RightOfUseAssetIncreaseDecreaseDueToModification	0	USD
CY2021Q1	kron	Right Of Use Asset Increase Decrease Due To Modification RightOfUseAssetIncreaseDecreaseDueToModification	-1741000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148979000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	141448000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2026000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151005000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143474000	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Net Income Loss NetIncomeLoss	-299200000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</span></div>
CY2022Q1	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost	305252000	USD
CY2022Q1	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax	2000	USD
CY2022Q1	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax	172000	USD
CY2022Q1	kron	Cash And Cash Equivalent And Debt Securities Available For Sale CashAndCashEquivalentAndDebtSecuritiesAvailableForSale	305082000	USD
CY2021Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Amortized Cost CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleAmortizedCost	331976000	USD
CY2021Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Gain Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedGainBeforeTax	2000	USD
CY2021Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale Gross Unrealized Loss Before Tax CashAndCashEquivalentAndDebtSecuritiesAvailableForSaleGrossUnrealizedLossBeforeTax	41000	USD
CY2021Q4	kron	Cash And Cash Equivalent And Debt Securities Available For Sale CashAndCashEquivalentAndDebtSecuritiesAvailableForSale	331937000	USD
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	138679000	USD
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	190698000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	154157000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	141239000	USD
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	12246000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2022Q1	us-gaap	Investments And Cash InvestmentsAndCash	305082000	USD
CY2021Q4	us-gaap	Investments And Cash InvestmentsAndCash	331937000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	292836000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	143014000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	12246000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	0	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	188923000	USD
CY2022Q1	us-gaap	Investments And Cash InvestmentsAndCash	305082000	USD
CY2021Q4	us-gaap	Investments And Cash InvestmentsAndCash	331937000	USD
CY2022Q1	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2022Q1	kron	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	661000	USD
CY2021Q4	kron	Debt Securities Available For Sale Accrued Interest DebtSecuritiesAvailableForSaleAccruedInterest	816000	USD
CY2022Q1	kron	Prepaid Equipment Service Contracts PrepaidEquipmentServiceContracts	446000	USD
CY2021Q4	kron	Prepaid Equipment Service Contracts PrepaidEquipmentServiceContracts	360000	USD
CY2022Q1	kron	Prepaid External Research And Development And Outside Services PrepaidExternalResearchAndDevelopmentAndOutsideServices	3086000	USD
CY2021Q4	kron	Prepaid External Research And Development And Outside Services PrepaidExternalResearchAndDevelopmentAndOutsideServices	3074000	USD
CY2022Q1	kron	Prepaid Software PrepaidSoftware	1054000	USD
CY2021Q4	kron	Prepaid Software PrepaidSoftware	624000	USD
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1691000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2644000	USD
CY2022Q1	us-gaap	Prepaid Rent PrepaidRent	517000	USD
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	527000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7455000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8045000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	18327000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	18139000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	3817000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	3259000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14510000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14880000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1258000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4570000	USD
CY2022Q1	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	50000	USD
CY2021Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	0	USD
CY2022Q1	kron	Accrued External Research And Development Current AccruedExternalResearchAndDevelopmentCurrent	5751000	USD
CY2021Q4	kron	Accrued External Research And Development Current AccruedExternalResearchAndDevelopmentCurrent	2655000	USD
CY2022Q1	kron	Accrued Outside Services Current AccruedOutsideServicesCurrent	1227000	USD
CY2021Q4	kron	Accrued Outside Services Current AccruedOutsideServicesCurrent	1598000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	42000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	240000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8328000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9063000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000	USD
CY2022Q1	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	1225000	USD
CY2021Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	1364000	USD
CY2022Q1	kron	Espp Withholdings Liability Current ESPPWithholdingsLiabilityCurrent	304000	USD
CY2021Q4	kron	Espp Withholdings Liability Current ESPPWithholdingsLiabilityCurrent	92000	USD
CY2022Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1529000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1456000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6590400	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.33
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1905502	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.41
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	131795	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.73
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	246029	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.15
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8118078	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.12
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M3D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11974000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.05
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	53500000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	49900000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7788000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5238000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36263000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-26086000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55839336	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55839336	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54152656	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54152656	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.65
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9962346	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8010023	shares
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26370000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26904000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2502000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2109000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30963000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31653000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	33465000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	33762000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1278000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1384000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3977000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5581000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5749000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5921000	USD
CY2022Q1	kron	Lessee Operating Lease Liability To Be Paid Year Four And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter	26707000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	47935000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14470000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	33465000	USD

Files In Submission

Name	View Source	Status
0001741830-22-000017-index-headers.html	Edgar Link	pending
0001741830-22-000017-index.html	Edgar Link	pending
0001741830-22-000017.txt	Edgar Link	pending
0001741830-22-000017-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kron-20220331.htm	Edgar Link	pending
kron-20220331.xsd	Edgar Link	pending
kron-20220331_cal.xml	Edgar Link	unprocessable
kron-20220331_def.xml	Edgar Link	unprocessable
kron-20220331_g1.jpg	Edgar Link	pending
kron-20220331_htm.xml	Edgar Link	completed
kron-20220331_lab.xml	Edgar Link	unprocessable
kron-20220331_pre.xml	Edgar Link	unprocessable
kronq1fy2022ex311.htm	Edgar Link	pending
kronq1fy2022ex312.htm	Edgar Link	pending
kronq1fy2022ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRON
Kronos Bio, Inc. Stock $kron

2022 Q1 Form 10-Q Financial Statement

#000174183022000017 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRON Kronos Bio, Inc. Stock $kron

2022 Q1 Form 10-Q Financial Statement

#000174183022000017 Filed on May 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRON
Kronos Bio, Inc. Stock $kron